GBT Announces Participation in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Global Blood Therapeutics (GBT) will participate in two upcoming virtual events: the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. ET and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The fireside chats will be accessible on GBT's website in the Investors section, with replays available for one month post-event. GBT, focused on sickle cell disease treatments, has developed Oxbryta® and is advancing its pipeline programs.
Details
News Market Reaction – GBT
The recorded move for GBT in the trading session of this news was +2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 2:00 p.m. ET. The company will also participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference, with the fireside chat available on Monday, November 22, 2021, at 10:00 a.m. ET.
The fireside chats will be available on GBT’s website at www.gbt.com in the Investors section. Replays will be archived and available for one month following each event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.